NEW YORK, Jan 10 – Qiagen Genomics said Wednesday that it has entered into three new licensing agreements involving its Masscode technology for high-throughput SNP genotyping.

The agreements, announced separately, involve Agilent Technologies, Japan’s Daiichi Pharmaceutical subsidiary of Daiichi Pure Chemicals (DPC), and the University of Washington School of Pharmacy.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.